STOCK TITAN

Eikon Therapeutics (EIKN) 10-Q Filings

EIKN NASDAQ

Here are the 10-Q quarterly reports from Eikon Therapeutics, Inc. (EIKN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow EIKN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EIKN filings page.

Rhea-AI Summary

Eikon Therapeutics, Inc. reported a third-quarter net loss of $86.112 million, compared with $71.139 million a year earlier, as research and development expense rose to $71.826 million from $59.313 million. Nine-month net loss was $257.479 million, versus $244.593 million in 2025, and net cash used in operating activities was $223.950 million, compared with $146.792 million.

At September 30, 2026, Eikon held $461.7 million in cash, cash equivalents and marketable securities; the company said it believes this balance will fund operations for at least one year from issuance of the financial statements. License agreements could require up to $630.0 million in development and regulatory milestones and up to $1.1 billion in sales milestones, plus tiered royalties based on licensed-product net sales. Eikon has no products approved for commercial sale and has never generated revenue from product sales. The company previously identified a material weakness in internal control over financial reporting.

Rhea-AI Summary

Eikon Therapeutics, Inc. is a late clinical-stage biopharmaceutical company developing medicines using a proprietary imaging and data platform. For the quarter ended June 30, 2026, it reported a net loss of $88.4 million, compared with $105.2 million a year earlier, driven mainly by research and development expense of $75.5 million and general and administrative expense of $17.9 million.

As of June 30, 2026, Eikon held cash, cash equivalents, and marketable securities of $531.2 million and total assets of $779.6 million, and had an accumulated deficit of about $1.1 billion. Management states these resources are sufficient to fund operations for at least one year. The company completed an IPO in February 2026, issuing 21.2 million shares at $18.00 per share, and converted all redeemable convertible preferred stock into common stock. Eikon discloses a material weakness in internal control over financial reporting linked to a prior-period restatement and outlines plans to remediate it while continuing to advance multiple product candidates, including EIK1001–EIK1006.

Rhea-AI Summary

Eikon Therapeutics, Inc. reported a quarterly net loss attributable to common stockholders of $82.9 million for the three months ended March 31, 2026, reflecting heavy investment in its drug pipeline. Research and development expenses were $70.0 million and general and administrative costs were $17.3 million, driving total operating expenses to $87.3 million.

During the quarter, Eikon completed its initial public offering at $18.00 per share, issuing 21.2 million shares for approximately $348.1 million in net proceeds, and converting all series of redeemable convertible preferred stock into 29.9 million common shares. As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $596.0 million, and the company believes this will fund operations for at least one year. Stockholders’ equity turned positive to $550.7 million, with an accumulated deficit of about $1.0 billion, and 54.1 million common shares were outstanding as of May 1, 2026.